BGN undergoes detectable overexpression in both RS- and LSCCs, and overexpression of this molecule has been previously described in numerous tumors, including endometrial, pancreatic, oesophageal squamous cell, gastric and prostate carcinomas [29,30,31,32,33]. Here, BGN is linked to prostate carcinoma.